• APRÈS RECONSTITUTION (POUR USAGE DE RECHERCHE) :

  • Réfrigéré (2–8°C) : 3–4 semaines

  • Congelé (-20°C) : 6–12 mois (en aliquotes)

  • Température ambiante : Max 24–48 h (🔴)

• Reconstitution : Eau bactériostatique (EBW) flacon multidoses.

• Demi-vie plasmatique : $\approx 7$ jours (injection sous-cutanée $1\times/\text{semaine}$).

• Instructions / Conseils : Dans les essais cliniques, délivré sous forme de stylo prérempli. Pour la recherche, reconstituer la poudre lyophilisée avec de l’eau bactériostatique (EBW), conserver au réfrigérateur et protéger de la lumière.

• Protocole : Injection sous-cutanée hebdomadaire. Une titration progressive est obligatoire : 0,3 mg/semaine (semaines 1 à 4) $\rightarrow$ 0,6 mg/semaine (semaines 5 à 8) $\rightarrow$ 1 mg/semaine (semaines 9 à 12) $\rightarrow$ 2,4 mg/semaine (semaines 13 et plus). Dans le cadre du CagriSema : une injection combinée unique de 2,4 mg + 2,4 mg/semaine. Administrer le même jour chaque semaine. Une surveillance médicale obligatoire est requise.

• Avertissement important : Ne pas associer avec d’autres agonistes des récepteurs du GLP-1 (Sémaglutide, Tirzépatide) en dehors d’un protocole CagriSema supervisé par un médecin. Le Cagrilintide peut masquer les symptômes d’hypoglycémie chez les patients diabétiques sous insuline.

• Après reconstitution (pour usage de recherche) :

  • Réfrigéré (2–8°C) : 3–4 semaines

  • Congelé (-20°C) : 6–12 mois (en aliquotes)

  • Température ambiante : Max 24–48 h

• Reconstitution : Eau bactériostatique (EBW) flacon multidoses.

• Consignes importantes : Dans les essais cliniques, délivré sous forme de stylo prérempli. Pour la recherche, reconstituer la poudre lyophilisée avec de l’eau bactériostatique (EBW), conserver au réfrigérateur et protéger de la lumière.

• Clean the rubber stopper of the peptide bottle and that of the bacteriostatic water bottle using an alcohol wipe.
• Using a sterile syringe, draw up the recommended amount of bacteriostatic water.
• Inject the water slowly along the inner wall of the peptide vial to avoid damaging the powder.
• Gently rotate the bottle in a circular motion until the powder is completely dissolved. Do not shake vigorously.
• Once the product has been reconstituted, immediately place the bottle in the refrigerator, at a temperature between 2°C and 8°C.

• Recommended dosing protocols vary depending on the specific needs and objectives of the research.
• The product is usually administered by subcutaneous injection using a sterile insulin syringe.
• Always ensure that hygiene rules are followed and that the injection site is thoroughly cleaned with an alcohol wipe before administration.
• Alternate injection sites regularly to minimize localized skin irritation or discomfort.
• Consult product-specific research guidelines or professional protocols to determine the exact frequency and duration of the cycle.

• Before reconstitution: store in a freezer at -20°C or lower for long-term storage, or in a refrigerator between 2°C and 8°C. Protect from direct light.
• After reconstitution: keep refrigerated between 2°C and 8°C. Do not freeze. Use within the recommended timeframe (generally 14 to 28 days depending on the peptide).

Sterile handling of bacteriostatic water is essential to guarantee optimal preservation and purity of your peptide solutions:

• Initial Disinfection : Carefully clean the rubber stopper of the bacteriostatic water bottle and that of the peptide with a wipe soaked in 70% alcohol before any handling.

• Accurate Sampling : Using a sterile syringe, collect the exact volume of bacteriostatic water required by your research protocol (usually 1 ml to 2 ml).

• Delicate Transfer : Insert the needle into the lyophilized powder vial at a slight angle, allowing the water to flow gently down the inner wall. Avoid splashing the liquid directly onto the powder.

• Dissolving without Shaking : Let the bottle stand for a few moments at room temperature, then gently swirl it in a circular motion until completely dissolved. Never shake the bottle vigorously.

• Post-Reconstitution Storage : Once the bacteriostatic water has been mixed with the peptide, immediately store the resulting solution in a refrigerator (between 2°C and 8°C) according to laboratory standards.

• Research Use Only : This product is formulated and intended exclusively for laboratory research and in vitro analysis by qualified personnel.

• Dilution Proportions : The volume of bacteriostatic water to be used depends directly on the reconstitution protocol of the peptide concerned (generally measured in milliliters to achieve the desired molar or mass concentration).

• Bacteriostatic agent : Contains sterile water with 0.9% benzyl alcohol added, which inhibits bacterial growth and preserves the integrity of the solution after multiple samplings over a prolonged period.

• Safety & Handling : Strictly adhere to current aseptic standards. Use sterile, single-use syringes and dispose of used materials according to laboratory safety procedures.

• Storage Temperature : Store unopened bottles at a stable room temperature (between 15°C and 25°C), away from direct sunlight and moisture.

• Post-Opening Storage : Once the bottle has been pierced for the first time, store it in the refrigerator (between 2°C and 8°C) to maintain the effectiveness of the bacteriostatic agent (0.9% benzyl alcohol).

• Duration of Use : Thanks to its formulation containing benzyl alcohol, the bottle can generally be used for multiple samplings over a maximum period of 28 days after the first opening, provided that strict aseptic rules are followed.

• Visual Inspection : Before each use, visually inspect the bottle. The solution should remain perfectly clear, colorless, and free from particles. If the seal is broken or the liquid is cloudy, discard the bottle immediately.

Proper reconstitution is essential to preserve the integrity and purity of the peptides. Follow these standardized laboratory steps for optimal preparation:

• Material Preparation : Disinfect your work surface and wipe the rubber caps of the peptide bottle and bacteriostatic water with a wipe soaked in 70% alcohol.

• Water Dosage : Using a sterile graduated syringe, take the precise amount of bacteriostatic water required (usually 1 ml to 2 ml depending on your dosage protocol).

• Gentle Injection : Insert the needle into the peptide vial, tilting the vial slightly so that the water flows down the inner wall. Never inject the water directly and forcefully into the center of the powder to avoid breaking the peptide chain.

• Natural Dissolution : Let the bottle sit for a few minutes at room temperature. Gently rotate it between your fingers in a light circular motion until completely dissolved. Never shake vigorously .

• Recommended Storage : Once reconstituted, immediately store the solution in a refrigerator (between 2°C and 8°C) in accordance with good laboratory practices.

• Research Use Only : This material and associated accessories are strictly intended for in vitro research and laboratory analysis by accredited professionals.

• Dosage Accuracy : The reconstitution volume and dosage calculation depends entirely on the specific research protocol established by the laboratory. It is recommended to use high-precision graduated syringes to ensure accurate measurements.

• Standardization of Measurements : Ensure that each sampling step is documented and that dilution coefficients are respected to guarantee the reproducibility of experimental results.

• Safety & Handling : Always handle syringes and needles with sterile gloves and immediately dispose of used material in an approved sharps container.

• Storage Conditions : Keep syringes and needles in their original sterile packaging, in a clean, dry place away from moisture and direct sunlight.

• Ambient Temperature : Maintain the equipment at a stable ambient temperature (between 15°C and 25°C) to preserve the integrity of the materials and rubber seals.

• Packaging Integrity : Remove items from their sterile packaging only immediately before use. If the individual packaging is damaged or opened, discard the material immediately.

• Safety & Hygiene : Keep out of reach of unqualified persons. Ensure compliance with current safety standards for the storage and disposal of laboratory equipment.

To ensure the integrity of your search results, follow these steps carefully:

1. Disinfection: Clean the rubber stopper of the Retatrutide bottle and your diluent with an alcohol swab. Allow to air dry.

2. Injection: Draw up the diluent with a sterile syringe. Inject it very slowly against the inner wall of the vial to preserve the peptide structure.

3. Dissolving: Allow the powder to dissolve naturally. Never shake the bottle; simply roll it gently between your fingers.

4. Inspection: The final mixture must be perfectly clear and free of visible particles.

5. Storage: Once reconstituted, it is essential to keep it refrigerated (2°C – 8°C) away from light.

• Research & Objective: The administration protocols and dosages of Retatrutide (10 mg) depend strictly on the specific objectives of the study and the experimental parameters ( in vitro or in vivo ).

• Recommended Dosage: In research literature and evaluation protocols, observed initial doses generally start at a low level (eg, between 1 mg and 2 mg per week) to observe the cellular response, with gradual adjustments depending on the scope of the experiment.

• Frequency: Applications are generally scheduled weekly due to the pharmacokinetic characteristics of the compound.

• Cycle duration: Experimental protocols usually extend over periods of 8 to 12 weeks or more, depending on the requirements of the research model.

To preserve the stability and molecular integrity of Retatrutide (10 mg) , observe the following storage conditions:

• Before reconstitution: Store the lyophilized vials in a refrigerator (between 2°C and 8°C) or in a cool, dry place, away from direct light, moisture and heat.

• After reconstitution: The reconstituted product must be kept refrigerated (between 2°C and 8°C). Do not freeze.

• Protection: Keep the bottle upright and avoid prolonged exposure to light.

• Mechanism: Binds to IGF-1R receptors on myocytes. Stimulates satellite cell differentiation. Activates mTOR protein synthesis. Inhibits muscle cell apoptosis.

• Reported effects: Muscle hyperplasia (new fibers). Increased strength and muscle volume. Significantly accelerated recovery. Reduction in body fat.

• Protocol: 20–100 mcg/day IM or SC, post-workout. Short cycle: 4–6 weeks maximum (risk of receptor desensitization). Requires glycemic monitoring.

• Important warning: Risk of hypoglycemia. Use reserved for experienced individuals under medical supervision.

R3 20 mg ke screenshot ke mutabiq Storage Instructions (Reconstituted Shelf Life / Storage) section ka content French mein yeh raha:

• After reconstruction:

  • Refrigerated ( $2–8^\circ\text{C}$ ): 2–3 weeks.

  • Frozen ( $-20^\circ\text{C}$ ): 3–6 months.

  • Ambient temperature: $< 4\text{h}$ .

• Recommended solvent: Acetic acid 0.1% (dissolution) $\rightarrow$ bacteriostatic water for dilution.

• Half-life: 20–30 hours (long half-life via plasma vs native IGF-1: $\sim 15\text{ min}$ ).

• Important instruction: Very fragile. Use diluted acetic acid (0.1%) as a solvent. Aliquot immediately and freeze.

Careful and sterile reconstitution is essential to guarantee the stability and purity of the lyophilized R3 30mg intended for in vitro research:

• Strict asepsis : Carefully clean and disinfect the rubber stopper of the R3 bottle and that of the bacteriostatic water using a wipe soaked in 70% alcohol before any intervention.

• Dilution Volume : Using a sterile syringe, take the precise amount of bacteriostatic water recommended by your experimental protocol (eg, 1 ml or 2 ml to facilitate the calculation of molar concentrations).

• Gentle Injection Through the Wall : Insert the needle into the peptide vial at a slight angle so that the water flows slowly down the inner wall. Never force the liquid abruptly into the center of the lyophilized powder.

• Dissolution without Shaking : Let the bottle stand for a few minutes at room temperature, then gently swirl it in a light circular motion until completely dissolved. Absolutely avoid shaking the bottle vigorously to prevent altering the peptide’s structure.

• Post-Reconstitution Storage : Once the solution has been reconstituted, immediately store the vial in the refrigerator (between 2°C and 8°C) in accordance with good laboratory practices.

• • Exclusive Research Use : This peptide is intended solely for in vitro research and laboratory analysis by qualified and accredited personnel.

  • Concentration Calculation : The volume of bacteriostatic water to add depends on the specific parameters of your experimental protocol (eg, precise volumetric titration for an appropriate molar ratio). Always use high-precision graduated equipment.

  • Standardization and Traceability : Carefully record dilution volumes, reconstitution dates and conditions of use in laboratory records to ensure reproducibility of tests.

  • Safety & Disposal : Strictly adhere to hygiene and safety guidelines. Handle with personal protective equipment and dispose of used sampling equipment in a specialized sharps container.

• • Storage Before Reconstitution : Store unopened lyophilized vials in a dry, clean place protected from light, preferably in a refrigerator (between 2°C and 8°C) or at controlled room temperature (according to specific long-term stability recommendations).

  • Post-Reconstitution Storage : Once reconstituted with bacteriostatic water, the vial must be immediately stored in a refrigerator (between 2°C and 8°C). Never freeze the reconstituted peptide solution.

  • Recommended Duration of Use : Use the reconstituted solution preferably within the time frame specified by laboratory protocols (generally within 14 to 28 days depending on aseptic conditions).

  • Visual Inspection : Before each withdrawal, inspect the bottle. The solution must remain clear and transparent. If it becomes cloudy or contains insoluble particles, dispose of the product immediately in accordance with safety regulations.

To ensure the integrity of your results, follow these steps carefully:

1. Disinfection: Clean the rubber stopper of the bottle and the diluent with an alcohol swab. Allow to air dry.

2. Injection: Draw up the diluent with a sterile syringe. Inject it very slowly against the inner wall of the vial to avoid degrading the peptide.

3. Dissolving: Allow the powder to dissolve naturally. Never shake the bottle; simply roll it gently between your fingers.

4. Inspection: The final mixture must be perfectly clear and free of particles.

5. Storage: Once reconstituted, it is essential to keep it refrigerated (2°C – 8°C) away from light.

• Research & Objective: Administration protocols and dosages depend strictly on specific research objectives and experimental models ( in vitro or in vivo ).

• Recommended Dosage: For R3 (5 mg), standard doses observed in the research literature generally vary between 100 mcg and 300 mcg per administration, depending on the scope of the study.

• Frequency: Applications are generally scheduled daily or according to a cycle defined by the parameters of the scientific protocol.

• Cycle duration: Experimental protocols usually last between 4 and 8 weeks , followed by an evaluation period.

To preserve the stability and molecular integrity of R3 (40 mg), observe the following storage conditions:

• Before reconstitution: Store the lyophilized vials in a refrigerator (between 2°C and 8°C) or in a cool, dry place, away from direct light and moisture.

• After reconstitution: The reconstituted product must be kept refrigerated (between 2°C and 8°C). Do not freeze.

• Protection: Keep the bottle upright and protect it from prolonged exposure to light.

To ensure the integrity of your results, follow these steps carefully:

1. Disinfection: Clean the rubber stopper of the bottle and the diluent with an alcohol swab. Allow to air dry.

2. Injection: Draw up the diluent with a sterile syringe. Inject it very slowly against the inner wall of the vial to avoid degrading the peptide.

3. Dissolving: Allow the powder to dissolve naturally. Never shake the bottle; simply roll it gently between your fingers.

4. Inspection: The final mixture must be perfectly clear and free of particles.

5. Storage: Once reconstituted, it is essential to keep it refrigerated (2°C – 8°C) away from light.

• Research & Objective: Administration protocols and dosages depend strictly on specific research objectives and experimental models ( in vitro or in vivo ).

• Recommended Dosage: For R3 (5 mg), standard doses observed in the research literature generally vary between 100 mcg and 300 mcg per administration, depending on the scope of the study.

• Frequency: Applications are generally scheduled daily or according to a cycle defined by the parameters of the scientific protocol.

• Cycle duration: Experimental protocols usually last between 4 and 8 weeks , followed by an evaluation period.

To preserve the stability and molecular integrity of R3 (5 mg), observe the following storage conditions:

• Before reconstitution: Store the lyophilized vials in a refrigerator (between 2°C and 8°C) or in a cool, dry place, away from direct light and moisture.

• After reconstitution: The reconstituted product must be kept refrigerated (between 2°C and 8°C). Do not freeze.

• Protection: Keep the bottle upright and protect it from prolonged exposure to light.

• AFTER RECONSTRUCTION (EGRIFTA®):

  • Refrigerated (2–8°C): 3 weeks max

  • Frozen: Do not freeze ( 🔴)

  • Room temperature: Not recommended ( 🔴)

• Reconstitution: Sterile water (Egrifta® kit — single use).

• Plasma half-life: $\approx 26$ minutes.

• Instructions/Advice: Store between 2 and 8°C. Do not freeze. Protect from light. Use within 3 weeks of reconstitution.

• Protocol: 2 mg/day subcutaneously (official indication). Injection in the evening before bedtime to optimize nocturnal growth hormone (GH) secretion. Required medical prescription.

• Important note: This is a prescription medication (Egrifta®). Off-label use should be discussed with a doctor.

• After reconstitution (Egrifta®):

  • Refrigerated (2–8°C): 3 weeks max

  • Frozen: Do not freeze

  • Room temperature: Not recommended

• Reconstitution: Sterile water (Egrifta® kit — single use).

• Important instructions: Store between 2 and 8°C. Do not freeze. Protect from light. Use within 3 weeks of reconstitution.

• Mechanism: Dual agonist of GIP and GLP-1 receptors. Increased satiety via GLP-1 (hypothalamus) and GIP. Direct adipocyte lipolysis via the GIP component. Slowing of gastric emptying.

• Reported effects: Weight loss of -22% (SURMOUNT trials – superior to Semaglutide). Glycemic control superior to Semaglutide. Less nausea than Semaglutide at comparable doses. Reduction in cardiovascular risk (studies in progress).

• Protocol: 2.5 mg/week SC (weeks 1–4), gradually titrated up to 15 mg/week. Weekly SC injection (pre-filled pen). Prescription and medical monitoring required.

• Important warning: Prescription medication. Never combine with Semaglutide or Retatrutide (GLP-1 overlap).

• Pre-filled pen (medical use):

  • Before opening: Until the expiry date.

  • After first use: 56 days max at $8^\circ\text{C}$ .

  • Frozen: Do not freeze.

• Important instructions: Store between 2-8°C before use. After opening: room temperature <30°C tolerated, max 56 days.